A LinkedIn post from Okami Medical highlights the company’s planned presence at the Society of Interventional Radiology (SIR) meeting in Toronto, with a focus on its LOBO HDBRAID Vascular Occluder and SENDERO delivery system for embolization procedures. The post promotes an educational session on April 11 featuring case-based learnings, along with a hands-on lab on April 13 where clinicians can trial the technology.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Okami Medical is actively engaging opinion leaders and end users in interventional radiology, which may support clinical adoption and evidence generation for its embolization portfolio. For investors, increased visibility at a major specialty conference could help strengthen the company’s competitive position in vascular occlusion and potentially support future commercialization efforts, though no financial or regulatory milestones are mentioned in the post.